cardiomyopathy disorder of the heart muscle
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients implanted with a Medtronic ProtectaTM ICD (VR or DR) or CRT-D, between 18-80 years of age, with a primary or secondary prophylactic indication for ICD therapy according to the current European guidelines, speaking and understanding Dutch, and providing written informed consent will be eligible to participate.
Exclusion criteria
Exclusion criteria: Patients with a life expectancy less than 1 year, with a history of psychiatric illness other than affective/anxiety disorders, on the waiting list for heart transplantation or with insufficient knowledge of the Dutch language will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study outcome is safety of Enhanced programming within 12 months after implantation (combined endpoint): all arrhythmic syncopes and other intervention-related safety events (either hospitalization, death or other serious adverse event due to Enhanced programming. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study outcomes are: number of adverse events (adverse events related to ICD shock with consequences and adverse events related to syncopal/near syncopal events); number of appropriate/inappropriate and successful/unsuccessful ATPs/shocks; quality of life and distress (anxiety/depression). | — |
Countries
Netherlands